Since 1994 we have provided screening libraries of lead-like molecules, macrocycles and fragments as well as research reagents and building blocks that have greatly enhanced the medicinal chemistry programs of our clients throughout the world.
With our R&D sites in Winston-Salem, NC and Moscow, Russia we can respond efficiently to the demands of our industrial and academic partners through collaborative engagement in many disciplines:
- Medicinal chemistry: hit identification, hit-to-lead, lead optimization, fragment based drug design (FBDD), structure based drug design (SBDD), parallel chemistry & purification
- Biology: assay validation, HTS, high content screening, cellular biology, ADMET and PK
- Compound collection management
Leveraging 20+ years of research experience, we have refined our powerful Compound-to-Target™ platform that facilitates the discovery of novel modulators of pharmacologically-relevant “difficult” targets and signaling pathways:
- Protein-Protein interactions
- WNT/ β-catenin
- Infectious diseases
Our technology is based on innovative chemistry enabling the creation of novel lead-like molecules and macrocycles supported by experimental biological testing to refine the design via synchronized target-based and phenotypic screening cascades. The platform provides valuable deliverables in the areas of oncology and infectious disease.